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http://dx.doi.org/10.1016/j.stemcr.2016.04.011SUMMARYAnalyzing contractile force, the most important and best understood function of cardiomyocytes in vivo is not established in human
induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM). This study describes the generation of 3D, strip-format, force-gener-
ating engineered heart tissues (EHT) from hiPSC-CM and their physiological and pharmacological properties. CM were differentiated
from hiPSC by a growth factor-based three-stage protocol. EHTs were generated and analyzed histologically and functionally. HiPSC-
CM in EHTs showed well-developed sarcomeric organization and alignment, and frequent mitochondria. Systematic contractility anal-
ysis (26 concentration-response curves) reveals that EHTs replicated canonical response to physiological and pharmacological regulators
of inotropy, membrane- and calcium-clock mediators of pacemaking, modulators of ion-channel currents, and proarrhythmic com-
pounds with unprecedented precision. The analysis demonstrates a high degree of similarity between hiPSC-CM in EHT format and
native human heart tissue, indicating that human EHTs are useful for preclinical drug testing and disease modeling.INTRODUCTION
The advent of human induced pluripotent stem cell
(hiPSC) technology and protocols to efficiently differen-
tiate cardiomyocytes (CM) (Burridge et al., 2012) have
opened the perspective to use hiPSC-CM for cardiac
research or drug development. This biotechnology
advancement also boosted the development of test systems
to evaluate hiPSC-CM electrophysiology (reviewed in
Hoekstra et al., 2012), impedance (Guo et al., 2013; Scott
et al., 2014), field potentials (Caspi et al., 2009; Harris
et al., 2013; Navarrete et al., 2013; Clements and Thomas,
2014; Riedel et al., 2014; Qu and Vargas, 2015), action po-
tentials and calcium transients with fluorescent dyes, and
cellular shortening video-optically (Lee et al., 2012; Lo-
pez-Izquierdo et al., 2014; Feaster et al., 2015; Pointon
et al., 2015). These assays may improve preclinical drug
development and safety toxicology, because current sys-
tems are based either on recombinant cell lines or animal
cells, both susceptible to typical shortcomings. HiPSC-
CM promise an intact, human cardiomyocyte context in
which a drug and/or principle is tested. Moreover, pa-
tient-specific cell lines offer (1) the perspective of testing
drugs in a wide spectrum of genetic backgrounds and (2)
individualized risk prediction and testing of adverse drug
effects. Different technologies have been employed for pre-
dictive toxicology application (Braam et al., 2010; PointonThis is an open access article under the Cet al., 2015), and many studies have successfully demon-
strated disease-specific phenotypes in hiPSC-CM from pa-
tients with inherited cardiac diseases (reviewed in Moretti
et al., 2013; Karakikes et al., 2015). Most test systems use
hiPSC-CM as 2D layers on rigid plastic cell-culture dishes
that do not allow the cells to perform physiological auxo-
tonic contractions (Nishimura et al., 2004). Contractile
function, the main feature of the heart, can only be
analyzed in a very restricted manner.
We have developed protocols to form 3D force-gener-
ating engineered heart tissues (EHTs; Eschenhagen et al.,
2012; Hirt et al., 2014). This follows the principle of hy-
drogel formation with dissociated cardiomyocytes in
casting molds and maintenance with a defined preload.
Cardiomyocytes remodel the hydrogel, align along force
lines, increase in size, and form a coherently beating syn-
cytium. Potential advantages of the EHT system for pre-
clinical drug development and safety toxicology are
2-fold. (1) It allows monitoring effects of drugs on all ma-
jor parameters of heart function: force, pacemaking
activity and contraction, and relaxation kinetics. (2) The
analysis is done under stable conditions that resemble car-
diac physiology, i.e., 3D heart-like muscle strips that
contract under auxotonic, work-performing, steady-state
conditions.
First publications with EHTs from human embryo-
nic stem cells or hiPSC-CM demonstrated the principalStem Cell Reports j Vol. 7 j 1–14 j July 12, 2016 j ª 2016 The Author(s) 1
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Cardiac Differentiation Protocol
Spontaneous beating started at days 9–11 of differentiation. Beating cells were dissociated, subjected to fluorescence-activated
cell sorting analysis (cTNT), and used for EHT generation (d14; see also Movies S4 and S5). EHTs started coherent beating at days
10–14 after casting and enabled for functional analysis (see also Movie S1; scale bar, 1 mm). Average contraction peaks of spontaneously
beating (black) and electrically paced EHTs (red; 1.5 Hz; 20–35 days after casting) in modified Tyrode’s solution with 1.8 mM
calcium are shown (n = 50 EHTs from seven independent experiments per group; depicted are mean ± SEM). Scale bars, 200 mm. See also
Figure S1.
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characterization (Schaaf et al., 2011; Tulloch et al., 2011;
Kensah et al., 2013; Nunes et al., 2013; Thavandiran
et al., 2013). However, neither we nor others have yet
shown that EHTs from hiPSC-CM are indeed suitable for
the proposed purpose, i.e., whether they faithfully replicate
effects on indicator compounds affecting rate, force, and
contraction kinetics. This is particularly important for
inotropes, since modulators of inotropy are a mainstay of
cardiac drug development and new concepts are urgently
needed (Francis et al., 2014). The present study therefore
set out to answer the following questions. (1) Do drugs
known to interfere with pacemaking mechanisms in the
sinoatrial node (SAN) affect the spontaneous beating rate
of hiPSC-EHTs? (2) Do positive and negative inotropic
drugs affect contraction force of hiPSC-EHTs in a manner
similar to that of human heart muscle strips? (3) Do drugs
with known and supposedly specific effects on individual
ion currents affect contractile function? (4) Is prolongation
of relaxation time a surrogate for prolongation of repolari-
zation and proarrhythmic risk?2 Stem Cell Reports j Vol. 7 j 1–14 j July 12, 2016RESULTS
Differentiation Results and Baseline Characterization
of hiPSC-EHTs
Formation of embryoid bodies (EBs) in spinner flasks re-
sulted in homogeneous EBs of 54 ± 1 mm(n = 198) diameter.
The average differentiation efficiency was 87% ± 9% (n =
20) with an input/output ratio of 1:1.2 ± 0.8 (hiPSC/
hiPSC-CM). Human EHTs started to beat spontaneously
and regularly 10–14 days after casting and continued
for several weeks (25- and 74-day-old EHT are shown in
Movies S1 and S2). Baseline contractility parameters
under auxotonic conditions (20- to 25-day-old EHTs from
seven different cardiomyocyte batches; n = 75/7) were
61 ± 2 bpm (frequency), 0.152 ± 0.006 mN (force),
0.120 ± 0.002 s (T1, contraction time), 0.163 ± 0.003 s
(T2, relaxation time), 1.51 ± 0.07 mN/s (maximal contrac-
tion velocity), and 1.11 ± 0.06 mN/s (maximal relaxation
velocity). Average peaks of spontaneously beating and
electrically paced EHTs (n = 50) are shown in Figure 1. Dur-
ing cardiac differentiation, expression of the pluripotency
Figure 2. Histological Evaluation of
hiPSC-EHTs
(A) Representative still view of a living EHT.
(B) Longitudinal section stained with H&E.
(C) Cross section stained for dystrophin.
(D) Longitudinal section stained for MLC2v.
(E) Whole-mount immunofluorescence
confocal microscopic section of EHT stained
with DRAQ5 (nuclei, blue) and a-actinin
(green).
(F) Confocal analysis of hiPSC-CM cultured
in 2D for 30 days stained with DRAQ5 (blue)
and antibodies against cardiac MLC2v (red)
and a-actinin (green).
(G and H) Whole-mount immunofluo-
rescence confocal microscopic section of
30- to 35-day-old EHTs stained with DRAQ5
(blue) and antibodies against a-actinin
(red; G) and caveolin-3 (green; G) or phal-
loidin (red; H) and an antibody against
junctophilin-2 (green; H).
(I) Transmission electron microscopy of
35-day-old EHT. Arrows indicate structures
resembling t tubules.
See also Figure S2.
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(MESP, VEGFR2) increased transiently, and expression of
cardiac genes increased progressively (Figure S1A). Differ-
entiated cardiomyocytes were mainly MLC2a+/MLC2v
and developed to an MLC2a/MLC2v+ cardiomyocyte
population in the EHT format (Figures S1B and S1C). The
non-cardiomyocyte fraction at the end of differentiation
was investigated by gene-expression analysis. Besides
cardiac genes, the most prominently expressed genes
were those typical for (myo)fibroblast-like cells, while
genes for other cell types were expressed below 1% of car-
diac gene expression level (Figure S1D).
Still pictures of live EHTs taken with the video camera of
the EHT setup (Figure 2A and Movie S1) demonstrated
macroscopically distinguishable muscle bundles in EHTs.
Histological analysis of 30- to 35-day-old EHTs revealed
structural anisotropy with cellular alignment in parallel
to the force lines spanning along the longitudinal axis
of the tissue (Figure 2B) and appearing as round, dystro-
phin-positive CM in cross sections (Figure 2C). CM in
EHTs were characterized by regular sarcomeric organiza-
tion of a-actinin and a high degree of MLC2v-positive
CM (Figures 2D and 2E), whereas CM cultured in 2D
showed poor sarcomeric organization and less cellularalignment (Figure 2F). Caveolin-3 immunofluorescence
provided initial evidence for immature t-tubule formation
by demonstrating punctual but irregular staining pattern
and areas with poorly organized caveolin-3-positive
structures as an indicator for developing caveolae (Fig-
ure 2G). This irregular staining pattern was also apparent
in EHTs stained with an antibody against junctophilin-2
(Figure 2H). Transmission electron microscopy (TEM)
confirmed orientation and alignment of sarcomeric struc-
tures with regular Z lines, and inconsistent I- and A-band
formation (Figure 2I). Average sarcomere length was 1.6 ±
0.1 mm (n = 20 sarcomeres); mitochondria were frequent
and exhibited mainly immature cristae-subtype with
sparse cristae formation. Tubular structures (60–80 nm
diameter) were detected in close proximity to Z lines.
Gene expression of ion channels and cardiac markers
indicated overall similar expression in EHT and 2D (Fig-
ures S2A and S2B). Microarray analysis (Table S1; NCBI
GEO accession number GEO: GSE80390) of differentiated
cardiomyocytes, EHT, and 2D CM samples revealed 5,687
significantly expressed genes (false-discovery rate [FDR]
<5%, Table S1). Probes below 0.1% FDR (n = 277) were
further investigated using clustering (Figure S2C) and
functional enrichment approaches (Table S2). SeveralStem Cell Reports j Vol. 7 j 1–14 j July 12, 2016 3
Figure 3. Modulation of Spontaneous
Beating Frequency of hiPSC-EHTs in
Modified Tyrode’s Solution
Replicates are indicated as EHTs/number of
independent experiments. Data are de-
picted as mean ± SEM (A and B) or scatter
plots with means (C and D).
(A) Ivabradine effect at 1.8 mM calcium;
n = 4/1.
(B) Effect of 100 nM isoprenaline (Iso),
10 mM ryanodine (Ryd), or isoprenaline af-
ter ryanodine preincubation (Ryd + Iso,
5 min) at 0.6 mM calcium; n = 4–8/1.
(C) Effect of SEA-0400 at 1 mM calcium (1 hr
incubation time); n = 12–16/2.
(D) Effect of tetrodotoxin (TTX) at 1.8 mM
calcium; n = 16/2.
See also Figure S3.
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LTCC; Na+/Ca2+-exchanger, NCX1; Na+/K+-ATPase; Na+/
H+-exchanger, NHE1; SR Ca2+-ATPase, SERCA; phospho-
lamban [PLN]) were detected in 2D and EHT by western
blot (Figure S2E).
Functional Characterization of hiPSC-EHTs
The basis for the characterization of the hiPSC-EHT model
are 26 concentration-response curves (CRC), depicted as
scatterplots in Figures S5–S7.
Pacemaker Mechanisms
To investigate pacemaker mechanisms in hiPSC-EHTs, we
analyzed the contraction pattern by video-optical
recording (Figure S3).We tested five compounds interfering
relatively selectively with the membrane clock (ivabradine
with hyperpolarization-activated cyclic nucleotide-gated
[HCN] channels), the SR-based calcium clock (ryanodine
with ryanodine receptors, SEA-0400 with NCX), or both
proposed pacemaker mechanisms (isoprenaline with PLN
and HCN channels) or sodium-channel activity (TTX).
Ivabradine (0.01–1 mM) concentration- and time-depen-
dently decreased spontaneous beating frequency with
half-maximal effects at 50 nM and almost complete inhi-
bition at 1 mM (Figures 3A and S7N). Ryanodine (10 mM)
decreased the spontaneous beating rate (from 47 ± 6 to
20 ± 2 bpm; n = 4) and antagonized the positive chrono-
tropic effect of isoprenaline (Figure 3B), which itself
amounted to +27% (from 47 ± 6 to 60 ± 4 bpm). The
NCX inhibitor SEA-0400 induced complex responses.
Some EHTs showed an increase in spontaneous beating
frequency and others a reduction, and some ceased beating
at high concentrations (10 mM, Figures 3C and S7O). TTX
concentration-dependently decreased the beating rate4 Stem Cell Reports j Vol. 7 j 1–14 j July 12, 2016with a threshold concentration of 300 nM (Figures 3D,
6B, S6B, and S6D).
Physiological Force Modulation
HiPSC-EHTs displayed a concentration-dependent positive
inotropic response to increasing extracellular calcium con-
centrations with an half maximal effective concentration
(EC50) of 0.6 mM calcium (n = 8; Hill slope 1.96; Figures
4A and S5A). Under pacing, EHTs followed electrical stimu-
lation between 1 and 2 Hz and partially lost capture above
2 Hz (Figure 4B). At pacing rates below 1 Hz, frequency-
control was incomplete due to higher spontaneous beating
frequency for some EHTs. An increase in beating rate be-
tween 1.0 and 2.0 Hz resulted in reduction of contraction
time and relaxation time (frequency-dependent acc-
eleration of relaxation [FDAR] 18%), but no change of
contractile force (no Treppe phenomenon; Figure 4C).
b-Adrenergic stimulation with isoprenaline (100 nM at
0.6 mM Ca2+, 2-Hz pacing frequency) led to an increase
in contractile force (+41% ± 7%; n = 13), no change in
contraction time T1 (2% ± 2%; n = 13), and a decrease
in relaxation time T2 (20% ± 4%; n = 13; Figure S5B).
The positive lusitropic effect of isoprenaline was antago-
nized by the muscarinic agonist carbachol (10 mM,
T2 +31% ± 5% compared with isoprenaline; n = 13; Fig-
ure 4D). Increasing the preload resulted in an increase in
contractile force from 43% ± 5% to 100% (maximum force;
n = 9). Maximum forcewas reached at 107% of slack length
(Figure 4E). Post-rest potentiation (PRP) was analyzed in
the presence of SEA-0400 (10 mM). This reduced the spon-
taneous beating rate and potentially aggravated the poten-
tiation: After 200 s of pacing (1.5 Hz) a 20-s-long pacing
pause was introduced before pacing was reinitiated. Com-
parison of the last contraction peak before and the first
Figure 4. Regulation of Contractile Function of hiPS-EHTs by Physiological Interventions
All experiments were carried out in modified Tyrode’s solution; replicates are indicated as EHTs/number of independent experiments; error
bars are SEM.
(A) Calcium concentration-response curve at 2-Hz electrical stimulation (n = 8/2).
(B) Beating rate at pacing frequencies between 0.6 and 3.0 Hz (n = 8/1).
(C) Force/contraction time/relaxation time-frequency relationship at 1.0 mM external calcium (n = 8/1).
(D) Response of electrically stimulated (2 Hz) EHTs to 100 nM isoprenaline (Iso) and 10 mM carbachol (CCh) at 0.6 mM calcium (n = 13/2).
(E) Frank-Starling mechanism. Increase in force in relation to increased preload at 1.8 mM calcium and 2 Hz (n = 5–9/1).
(F) Post-rest potentiation of EHTs at 1 mM calcium in the presence of 10 mM SEA-0400. Representative example (20 s rest, pacing with
1.5 Hz) and statistical evaluation (n = 8/1).
See also Figure S4.
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Figure 5. Regulation of Contractile Function of hiPSC-EHTs by Inotropic Drugs
Average contraction peaks before (black) and after (red) the respective inotropic drug intervention.
(A–H) Positive inotropic drugs (A–F) were tested at submaximal (0.5–0.6 mM), and negative inotropic drugs (G and H) at high (1.8 mM; H)
and submaximal (0.5 mM; G) calcium concentrations. Depicted is the electrically stimulated (1.5–2 Hz) mean relative force in percentage
of baseline maximum ± SEM in modified Tyrode’s solution; replicates are indicated as EHTs/number of independent experiments.
(A) calcium (5 mM; n = 8/2). (B) ouabain (100 nM; n = 6/2). (C) Bay K-8644 (300 nM; n = 4/1). (D) EMD-57033 (10 mM; n = 4/1).
(E) isoprenaline (100 nM; n = 4/1). (F) rolipram (10 mM) + isoprenaline (100 nM, red) versus isoprenaline (100 nM, black; n = 11/2).
(G) ryanodine (0.3 mM, red; 10 mM, blue; n = 6/2). (H) verapamil (1 mM; n = 18/2).
See also Figure S5.
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ure 4F). The selective inhibitor of the slowly activating
delayed rectifier current IKs, HMR-1556, was tested in the
presence of b-adrenergic activation and IKr inhibition,
a protocol that revealed maximal contribution of IKS to
repolarization in human ventricular myocardium (Jost
et al., 2005). HMR-1556 slightly reduced the isoprenaline-
stimulated spontaneous beating rate, but failed to affect
relaxation time or force, whereas E-4031 increased relaxa-
tion time by +82% in an isoprenaline-sensitive manner
(n = 4/1; Figure S4).
Pharmacological Force Regulation
We analyzed the effect of positive and negative cyclic AMP
(cAMP)-dependent and -independent inotropic modula-
tors (calcium, ouabain, Bay K-8644, EMD-57033, isoprena-
line, rolipram, ryanodine, and verapamil) under rate
control (1–2 Hz). Average contraction peaks are depicted
in Figure 5 (complete CRCs are shown in Figure S5). These
peaks demonstrate canonical inotropic changes for all
compounds tested, associated with characteristic changes
in contraction kinetics. Ca2+, ouabain, and verapamil
modulated force without a change in contraction kinetics,
while the increase in force development in the presence of
the cAMP-dependent drugs isoprenaline and rolipram was
accompanied by the typical hastening of relaxation (posi-
tive lusitropic effect). Conversely, the Ca2+ channel agonist6 Stem Cell Reports j Vol. 7 j 1–14 j July 12, 2016Bay K-8644 and the myofilament Ca2+ sensitizer EMD-
57033 markedly prolonged relaxation (negative lusitropic
effect). Ryanodine displayed typical biphasic responses,
with negative inotropic effects at low (0.3 mM) and positive
inotropic effects at high (10 mM) concentrations and a
pronounced increase in contraction time (T1), as shown
for myocardium tissue (Sutko and Willerson, 1980).
Modulators of the Cardiac Ion Channels
Antagonists and agonists of ion channels were analyzed in
spontaneously beating EHTs (Figures 6 and S6). Delayed
inactivation of the fast sodium current INa by ATX-II or acti-
vation of the L-type calcium current ICa,L by Bay K-8644
prolonged relaxation time T2 as did E-4031, a selective in-
hibitor of the repolarizing, rapidly activating delayed recti-
fier current IKr. ATX-II had the most pronounced effect
(556% ± 31% of baseline; see also Movie S3), Bay K-8644
mainly inhibited early relaxation, and E-4031 induced
typical after-contractions. Conversely, NS-1643, an agonist
of IKr, concentration-dependently reduced T2, which was
accompanied by increased spontaneous beating frequency
and an increase in contractile force. At high concentrations
(0.1 mM) EHTs demonstrated an irregular beating pattern,
indicated by high scatter for all contractility parameters
(Figures 6D and S6G). TTX slowed the spontaneous beating
rate as seen before (Figure 3D), but did not have a major ef-
fect on force or contraction kinetics (Figure S6D). The ICa,L
Figure 6. Effect of Specific Ion-Channel
Modulators on Spontaneous Contractions
of hiPSC-EHTs
Data are depicted as single values and
mean; replicates are indicated as EHTs/
number of independent experiments.
(A) Regular spontaneous beating pattern
under baseline condition (left) and 3 hr
later (time control, right).
(B–D) Concentration-response curves (B)
Left: ATX-II (INa gating inhibitor, agonist;
n = 20/2); right: TTX (INa antagonist;
n = 16/2). (C) Left: Bay K-8644 (ICa,L
agonist; n = 8/2); right: verapamil (ICa,L
antagonist; n = 19/2). (D) Left: NS-1643
(IKr agonist; n = 20/3); right: E4031 (IKr
antagonist; n = 20/3). Depicted are re-
presentative original recordings and con-
centration-response curve for the most
sensitive contraction parameter (T2, relax-
ation time at 80% relaxation, BPM, beats
per minute). Blue arrows indicate published
EC50/IC50 values (Oliveira et al., 2004;
Kaufmann et al., 2013; Bechem and
Schramm, 1987; Ferry et al., 1985; Casis
et al., 2006; Zhou et al., 1998). Statistical
analysis was conducted by one-way ANOVA
with Dunnett’s post test versus baseline
conditions (BL) for experiments with R3
independent experiments; *p < 0.05.
See also Figure S6.
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reased contractile force (as seen before under electrical
pacing, Figure 5H) and had only slight effects on contrac-
tion kinetics (Figure S6F). The expression of the respective
ion channels was verified as stated above (Figure S2). To
examine the compatibility of this protocol with cardio-
myocytes from commercial sources, we also generated
EHTs with Cor.4U and iCell CM. Figure S6A shows sponta-
neous and electrically stimulated average contraction
peaks of Cor.4U and iCell EHTs compared with the in-house reference cell line differentiated with the protocol
described herein. The EHTs from these commercial cell
lines responded similarly to the aforementioned ion-chan-
nel modulators (Figure S6B).
Proarrhythmic Compounds
Drug-induced increase in action potential duration
(APD90) is an important indicator for proarrhythmic cardi-
otoxicity (Redfern et al., 2003). The results with the ion-
channel model compounds ATX-II, Bay K-8644, and
E-4031 indicated that relaxation time T2 of hiPSC-EHTsStem Cell Reports j Vol. 7 j 1–14 j July 12, 2016 7
Figure 7. Correlation Analysis
Correlation between threshold value (THV) for prolongation of
relaxation time (T2, EHT) and increase in APD90 (10%–20%, Red-
fern et al., 2003), Pearson correlation R2 = 0.80. See also Figure S7.
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time or APD90. We therefore determined the effect of ten
known proarrhythmic compounds and, in line with the
often complex, nonselective actions of these compounds,
observed concentration-dependent effects on spontaneous
beating frequency, force, and T2 (Figures S7A–S7J). We
plotted threshold values of T2 prolongation against pub-
lished concentrations of these compounds, increasing
ADP90 by 10%–20% (Figure 7; Redfern et al., 2003). This
analysis demonstrates a very strong correlation between
these two parameters (correlation coefficient R2 = 0.80).
On the other hand, cardio-safe drugs (verapamil, ampi-
cillin, paracetamol, aspirin; Figures S6F and S7K–S7M) did
not affect T2 in this model.DISCUSSION
In this study we evaluated themorphology and function of
engineered 3D heart muscle strips (EHTs) from hiPSC-CM
and their suitability for drug screening. The protocol allows
analysis of contractile force with high levels of automation
but requires 13 106 cells per EHTand 14 days of incubation
time after casting. Our main findings are as follows. (1) The
EHT format supports excellent heart muscle formation and
morphologicalmaturation of hiPSC-CM. (2)Modulation of
beating frequency by isoprenaline, ivabradine, ryanodine,
SEA-0400, and TTX suggests both calcium- and mem-
brane-clock mechanisms to be involved in spontaneous
pacemaking of hiPSC-CM/EHTs and an overall similarity
with newborn SAN pacemaking. (3) Human iPSC-EHTs
exhibited a positive force-length relationship and FDAR
and PRP, but a neutral force-frequency relationship. (4)
Canonical responses to cAMP-dependent and -indepen-8 Stem Cell Reports j Vol. 7 j 1–14 j July 12, 2016dent positive and negative inotropic drugs were observed.
(5) There was high sensitivity and specificity for selective
ion-channel modulators; several proarrhythmic and safe
drugs make hiPSC-EHT a promising model for preclinical
drug screening.
Less than a decade after the establishment of the first pro-
tocol for the generation of hiPSC (Takahashi et al., 2007),
CM can now be differentiated from hiPSC at high effi-
ciency and are commercially available. Thus, hiPSC-CM
are increasingly used for biomedical applications and
have a chance to partially replace the mouse, with its
known limitations, as the standardmodel in cardiovascular
research. Yet the true value of hiPSC remains controversial,
in part because of limited functional readout assays. Our
study addressed these issues and tried to answer via a sys-
tematic approach to what extent the automated 24-well
hiPSC-EHT assay is suitable as a robust, high-content con-
tractile force assay.
The experimental design of this model provides several
differences to standard 2D culture: EHTs are anchored be-
tween two flexible silicone posts, which generate a preload,
and EHTs perform auxotonic contractile work (the physio-
logical form of cardiac contraction) against elastic posts.
This results in macroscopically distinguishable muscle
bundles, a high degree of CM alignment and orientation,
good sarcomeric organization, and cross-striated CM
approaching the classical rod shape of adult ventricular
myocytes. These results compare favorably with human
embryonic stem cell- and hiPSC-CM cultured in classical
monolayers that are polymorphic and small, isotropically
oriented, and have disarrayed sarcomeres and very imma-
ture ultrastructural organization (reviewed in Yang et al.,
2014). Furthermore, TEM, confocal immunofluorescence
microscopy, and western blot analysis revealed that CM
in EHTs have a relatively high mitochondrial density and
express classical calcium-handling proteins. TEM and
staining for caveolin and junctophilin are compatible
with nascent t tubules, but the data clearly do not qualify
as proof of an established t-tubular system in hiPSC-CM
in EHTs. Others have shown that culture time is important
for the structural and functional development of hiPSC-
CM in 2D (Lundy et al., 2013) and that 1-year-old CM
cultured at very low density exhibits increased size, longer
and better organized sarcomeres, greater transcript levels of
cardiacmarker proteins, longer action potentials, and signs
of metabolic switch that could be mimicked by overex-
pressing the microRNA let-7 (Kuppusamy et al., 2015).
Since EHTs are cultured for only 2–3 weeks before the first
measurements, other factors such as the 3D heart muscle-
like environment and load likely participate in this de-
velopment process. The impact of load on cardiomyocyte
development is also supported by a recent study in
neonatal rat EHTs demonstrating that increasing the load
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logical cardiac hypertrophy in rat EHTs (Hirt et al., 2012),
indicating that culture under isometric conditions (stiff
posts or 2D cultures on plastic surfaces) may in fact induce
a pathological phenotype. Somewhat surprisingly, EHTs
could readily be generated not only from hiPSC-CM prepa-
rations with 60%–90% purity, but also from two commer-
cially available hiPSC-CM (CDI, Axiogenesis), which, by
genetic selection, are essentially free of non-myocytes,
suggesting that previous findings of a mandatory require-
ment of 25% non-cardiomyocytes in collagen-based EHTs
(Naito et al., 2006) do not apply for human tissues gener-
ated with fibrin.
Contractile force in CM is the result of a fine-tuned inter-
play between electrical activation, calcium handling, and
myofilament activation. To obtain a comprehensive pic-
ture of inotropic regulation in hiPSC-EHT, we analyzed
the effects of eight compounds (calcium, ouabain, Bay
K-8644, EMD-57033, isoprenaline, rolipram, ryanodine,
and verapamil) that modulate contractile function by
different modes of action. The data suggest that the
hiPSC-EHT model replicates characteristic effects on ino-
tropy and kinetics of contraction. The level of precision
in replicating inotropic effects in hiPSC-EHTs is, to the
best of our knowledge, unmatched by other approaches.
For example, edge detection in 2D hiPSC-CM demon-
strated high sensitivity and specificity in detectingmodula-
tors of inotropy, but failed to discriminate positive from
negative inotropic agents (Pointon et al., 2015). The posi-
tive inotropic effects described in our study are smaller
than in human non-failing heart tissue (Figure S5F). These
differences are likely related to a lack of full maturation of
CM in hiPSC-EHTs: Mitochondrial density and substruc-
ture, sarcomeric organization, intercellular connections,
and t tubules are still clearly less developed in hiPSC-CM
in EHTs than in native heart tissue. EHTs beat spontane-
ously, regulation of contractile function by physiological
interventions was smaller, and a force-frequency relation-
ship was absent. A key prerequisite for inotropic responses
of CM is the precise spatial configuration of t tubules and
sarcoplasmic reticulum. Even though PRP indicated func-
tional sarcoplasmic reticulum and TEM analysis/caveolin-
3/junctophilin-2 immunofluorescence suggests tubular
structures in close proximity to Z lines, the irregularity
and the small size indicate a very immature t-tubule/SR sys-
tem. In native myocytes, the t-tubule microarchitecture is
highly organized with distances to the SR of 12–15 nm.
Small deviations of the spatial distance have been associ-
ated with altered calcium-induced calcium-release mecha-
nism (Go´mez et al., 1997). Themuch greater abnormalities
of the t-tubule/SR organization in hiPSC-CMwould also be
compatible with the lack of a force-frequency relationship.
Along the same lines, detubulation of rat myocytes byformamide-induced osmotic shock was associated with
prolonged contraction peaks and calcium transients, and
lack of a positive force-frequency relationship, but a
preserved FDAR, positive force-calcium relationship, and
positive PRP (Ferrantini et al., 2014). A study comparing
human ventricular heart tissue of newborns (<2 weeks)
and infants (3–15 months) observed t tubules, positive
force-frequency relationship, and FDAR in infants, but
only FDAR in newborns (Wiegerinck et al., 2009). PRP is
directly related to the capacity of the SR to store and release
calcium. The small PRP in hiPSC-EHTs suggest that the SR is
incompletely developed, but functional. The link between
small PRP and immaturity is also supported by a previous
study demonstrating an increase in PRP with rabbit cardio-
myocyte maturation between postnatal days 1–4, 14–21,
and >180 (Boucek et al., 1987). On the other hand, while
non-failing human heart tissue has been mainly evaluated
under isometric conditions, force in hiPSC-EHTs is
measured under physiological auxotonic conditions. The
impact of this difference is not well characterized, but
one study demonstrated 50% lower forces for auxotonic
versus isometric conditions in adult rat ventricular CM
(Nishimura et al., 2004).
Pacemaking in SAN cells is a complex process, explained
by a combination of ion fluxes across the sarcolemmal
membrane and the SR, designated as the calcium andmem-
brane clocks (Lakatta et al., 2010). The mechanisms of
spontaneous beating in hiPSC-CM are not well under-
stood. Previous studies identified If current in hiPSC-CM
(Ma et al., 2011). The marked efficacy and potency (EC50
 50 nM) of the If inhibitor ivabradine to reduce the
beating rate in our study provide evidence for a major
role of this current and, therefore, the membrane clock,
for pacemaking in hiPSC-EHTs. Both potency and efficacy
of ivabradine to decrease the beating rate in hiPSC-EHTs
were much greater than in spontaneously beating right
atria/SAN preparations of adult wild-type mice examined
under similar conditions (Mesirca et al., 2014; no effect at
50 nM, 50% reduction at 1,000 nM). The datamirror results
of genetic deletion of HCN4 in mice, which was embryon-
ically lethal (Stieber et al., 2003), indicating a greater role of
If for pacemaking in the developing heart. On the other
hand, the effect of isoprenaline, acting by stimulating
both the cAMP-sensitive If and Ca
2+ uptake into the SR,
was smaller in hiPSC-EHTs than in native SAN preparations
(+30% versus +50% in mice; Mesirca et al., 2014). The
isoprenaline effect was blocked by ryanodine at a high con-
centration (10 mM), suggesting that regulation of SR Ca2+
loading plays a major role in the isoprenaline-induced
tachycardia in thismodel. Ryanodine itself reduced sponta-
neous beating frequency by 50%, similar to data in the
intact canine SAN (Joung et al., 2009). Together with the
rate-reducing effect of the NCX blocker SEA-0400 atStem Cell Reports j Vol. 7 j 1–14 j July 12, 2016 9
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clock mechanisms contribute to pacemaking in hiPSC-
EHTs and that membrane regulation by If is involved in
these cells. The contribution of If is in line with previous
electrophysiological characterization of hiPSC-CM (Ma
et al., 2011), but has not been observed in another
hiPSC-CM model (Zhang et al., 2015). Reasons for the
difference are unknown, but the clear concentration and
time dependence and low half maximal inhibitory concen-
tration (IC50) of ivabradine in our experiments provide
strong evidence for a specific effect. A suppression of spon-
taneous beating was also observed in the presence of TTX
(1 mM). While TTX-sensitive sodium currents are not
assumed to play a role in pacemaking in the adult SAN,
50% of newborn rabbit SAN cells express TTX-sensitive
sodium currents, and this fraction decreased to 10% in
adult animals (Baruscotti et al., 1996). These data suggest
that pacemakingmechanisms in hiPSC-CM/EHTs resemble
that of newborn SAN cells.
Modulation of cardiac repolarization is a sensitive issue
in drug development, and analyses of drug effects on one
of the main repolarizing currents, IKr, assayed in human
ether-a-go-go-related gene (hERG)-expressing cell lines,
are mandatory (Kramer et al., 2013; Okada et al., 2015).
EHTs are not well suited for the determination of action
potentials (e.g., with sharp microelectrodes), but offer
simple and robust measurements of contraction kinetics
under steady-state conditions. We therefore tested the
hypothesis that drug effects on cardiac repolarization of
hiPSC-EHTs can be detected by affections of the relaxa-
tion time T2 as previously demonstrated in rat EHTs
(Eder et al., 2014). Indeed, stimulators (i.e., inhibitors
of inactivation) of the depolarizing fast sodium current
INa (ATX-II), activators of L-type calcium current ICa,L
(Bay K-8644), and inhibitors of the repolarizing rapidly
activating delayed rectifier current IKr (E-4031) concentra-
tion-dependently prolonged T2, while activation of IKr
with NS-1643 abbreviated T2. Threshold concentrations
matched well with published IC50 or EC50 values on
the respective channels (Figure 6). The Bay K-8644-medi-
ated prolongation of relaxation time in spontaneously
beating hiPSC-EHTs is in line with previous electrophys-
iological findings in hiPSC-CM, which revealed an atyp-
ical response to Bay K-8644 with a blunted increase in
L-type calcium current amplitude and prolonged activa-
tion and inactivation kinetics (Kang et al., 2012; Ji
et al., 2014). Effects of IKs current inhibition could not
be demonstrated in hiPSC-EHT even under adrenergic
stimulation and IKr block. This is in line with previous
studies reporting small IKs currents of 0.31 pA/pF in 5
out of 16 analyzed hiPSC-CM (Ma et al., 2011) and in-
sensitivity of hiPSC-CMs to IKs current inhibition in
multi-electrode arrays under blinded conditions (Qu10 Stem Cell Reports j Vol. 7 j 1–14 j July 12, 2016and Vargas, 2015). The data collectively indicate that
IKs contributes only little to repolarization of hiPSC-
CM. Taken together, the experiments with model com-
pounds show high sensitivity of hiPSC-EHTs in detecting
the effects of ion-channel modulators as alteration in T2.
IKs is a notable exception.
Obviously, T2 changes are not specific for certain alter-
ations in ion current, as modulators with different modes
of action (ATX-II, Bay K-8644, E-4031) all result in similar
changes. Moreover, relaxation time was also prolonged by
EMD-57033, a relatively pure calcium sensitizer that pro-
longs relaxation by its direct effect on the myofilaments,
and relaxation time was shortened by the cAMP-depen-
dent drugs isoprenaline and rolipram, acting via phos-
phorylation of PLN and several myofilament proteins
(Figure 5). Interestingly, neither verapamil nor TTX
affected relaxation time. Their effect was visible as a con-
centration-dependent decrease in force and rate, respec-
tively. The lack of verapamil effects on T2 is important
for two reasons. (1) It is consistent with the effect of vary-
ing extracellular Ca2+ concentrations, strongly affecting
peak force but not contraction kinetics. (2) Verapamil
blocks IKr in addition to ICa,L and is a classic example of
a drug that would have failed in hERG assays, but has
never been associated with proarrhythmic effects or QT
prolongation. The lack of a T2 signal in hiPSC-EHTs is
in line with clinical safety. Thus, the hiPSC-EHT system
offers a high-content readout of contractile function,
which integrates effects on depolarizing and repolarizing
ion currents, myofilaments, and SR-based Ca2+ cycling
without directly indicating the respective mechanism of
action.
It seems, therefore, that this system is well suited for an
initial screening of cardiac effects of drugs. The ability to
detect the effects of ion-channel modulators was further
challenged with a set of (previously) approved drugs, clas-
sified for their different potential to induce torsades-de-
pointes arrhythmia (Redfern et al., 2003). The correlation
depicted in Figure 7 demonstrates that prolongation of
T2 in hiPSC-EHTs is a sensitive surrogate for APD90 pro-
longation. Given the key role of APD prolongation in
drug-induced cardiac proarrhythmia (Fermini et al.,
2015), a surrogate for APD prolongation might address an
important aspect of in vitro cardiac safety assessment.
This conclusion is strengthened by the lack of T2 effects
of four compounds known to be safe (aspirin, paracetamol,
ampicillin, and verapamil).
In conclusion, this study analyzes the contractile force of
hiPSC-CM in the hiPSC-EHTmodel. Characteristic changes
in contractile force are described for several physiological
and pharmacological assays replicating findings of ex
vivo non-failing human heart tissue, suggesting a high
versatility of the hiPSC-EHT model as in vitro test system.
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Generation of Human Engineered Heart Tissue
Spontaneously beating cardiomyocytes (day 14 of differentiation
culture; Movies S4 and S5) were washed twice with PBS and di-
gested with collagenase II (Worthington, LS004176; 200 U/ml
Ca2+-free HBSS [Gibco, 14175-053] with 1 mM HEPES [pH 7.4],
10 mM Y-27632, and 30 mM N-benzyl-p-toluene sulfonamide
[TCI, B3082]) for 3.5 hr at 37C (5% CO2, 21% O2). The dissoci-
ated cells were washed (Ca2+-containing DMEM [Biochrom,
F0415] with DNase [12 mg/ml; Sigma-Aldrich, D8764]; centrifuga-
tion at 100 3 g for 15 min) and resuspended in basic medium
(Ca2+-containing DMEM with 1% penicillin/streptomycin). Cell
count was determined (CASY) and cell concentration adjusted
to 10–15 3 106 cells/ml. For determination of differentiation
efficiency, 2 3 105 cells were subjected to fluorescence-activa-
ted cell sorting analysis with the directly labeled cTNT anti-
body (Miltenyi, 130-106-745; 1:10). Fibrin-based human EHTs
were generated in agarose casting molds with solid silicone
racks as previously described (Hansen et al., 2010; Schaaf et al.,
2014). In brief, casting molds were generated with agarose
(2% in PBS [Invitrogen, 15510-019]) and custom-made Teflon
spacers in 24-well plates (Nunc, 122475). Custom-made silicone
racks were placed on the 24-well plates. Cells (final concentration
10 3 106 cells/ml) were mixed with 100 ml/ml Matrigel (BD
Bioscience, 256235), 5 mg/ml bovine fibrinogen (200 mg/ml in
NaCl 0.9% [Sigma, F4753] plus 0.5 mg/mg aprotinin [Sigma,
A1153]), and 23 DMEM (matching the volume of fibrinogen
and thrombin for isotonization), and EHTs were generated with
100 ml per EHT (1 3 106 cells), 10 mM Y-27632, and 3 U/ml
thrombin (100 U/ml [Biopur, BP11101104]). The cell mix was pi-
petted into agarose casting molds around silicone posts. After
fibrin polymerization (37C, 2 hr) the silicone racks with attached
fibrin gels were transferred to new 24-well plates and cultured for
4–6 weeks (37C, 40% O2, 7% CO2). The culture medium con-
sisted of DMEM, 1% penicillin/streptomycin, 10% horse serum
(Gibco, 26050), 10 mg/ml insulin, and 33 mg/ml aprotinin.
Culture medium was changed on Mondays, Wednesdays, and Fri-
days. After 10–14 days in culture, human EHTs displayed sponta-
neous coherent, regular beating deflecting the silicone posts, and
allowed video-optical contraction analysis. Commercial hiPSC-
CM (CDI, iCell; Axiogenesis, Cor.4U) were used for comparison.
Cells were thawed or dissociated according to instruction man-
uals, and cells counted (CASY) and EHTs prepared as stated above.Contractile Analysis of Human EHTs
Contractile analysis was performed on 20–40-day-old EHTs in
modified Tyrode’s solution (120 mM NaCl, 5.4 mM KCl, 1 mM
MgCl2, 0.1–5 mM CaCl2, 0.4 mM NaH2PO4, 22.6 mM NaHCO3,
5 mM glucose, 0.05 mM Na2EDTA, and 25 mM HEPES) pre-
equilibrated overnight (37C, 7% CO2, 40% O2). Analysis of
contractile force was performed by video-optical recording as
previously described (Hansen et al., 2010; Schaaf et al., 2011;
Figure S1) on a setup available from EHT Technologies. When
indicated, EHTs were electrically stimulated (2 V, 0.5–5 Hz, im-
pulse duration 4 ms) with carbon electrodes as previously
described using a Grass S88X stimulator (Hirt et al., 2014).The contraction peaks were analyzed in terms of frequency,
force, and contraction (T1) and relaxation time (T2) at 80% of
peak height (Figure S3).Statistical Analysis
According to journal guidelines, statistical analyses were only
performed (GraphPad Prism software 5.0) for experiments with
R3 independent experiments (EHTs from R3 independent car-
diomyocyte differentiations). Data are expressed as mean ±
SEM in bar graphs (except Figure S2: mean ± SD) and curves,
or as single values and mean in scatterplots. Data in the text
are expressed as mean ± SD. Differences between groups were
analyzed by one-way ANOVA followed by Dunnett’s (all
compared with baseline) post hoc multiple comparisons. Results
were considered statistically significant (*) if the p value was less
than 0.05. Average contraction peaks were generated from at
least ten contraction peaks of several EHTs as indicated in the
respective replicate number. These are depicted as mean ± SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, two tables, and five movies and can be
found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2016.04.011.
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